Loading...
Akebia Q1 2025 Earnings Report
Akebia Therapeutics reported strong first quarter 2025 financial results, driven by the initial U.S. launch of Vafseo® and increased Auryxia® sales, leading to a net income of $6.1 million.
Key Takeaways
Akebia Therapeutics reported a net income of $6.1 million for Q1 2025, a significant improvement from a net loss of $18.0 million in Q1 2024, primarily due to total revenues increasing to $57.3 million, driven by the successful U.S. launch of Vafseo® and strong Auryxia® sales.
Vafseo® (vadadustat) U.S. product launch generated $12.0 million in net product revenues in Q1 2025.
Total Q1 2025 net product revenues reached $55.8 million, contributing to overall revenue growth.
The company's balance sheet was bolstered by a $50 million underwritten public offering, increasing cash and cash equivalents to $113.4 million.
Net income for Q1 2025 was $6.1 million, a substantial improvement compared to a net loss of $18.0 million in the prior year period.
Akebia
Akebia
Akebia Revenue by Segment
Revenue by Segment
Vafseo Net Product Revenue
CapyFin.comAuryxia Net Product Revenue
CapyFin.comLicense, Collaboration & Other Revenue
CapyFin.com Forward Guidance
Akebia Therapeutics plans to continue driving Vafseo adoption across all dialysis providers, initiate a Phase 3 clinical trial for vadadustat in late-stage CKD patients not on dialysis, and believes it is financed to achieve profitability based on its current operating plan.
Positive Outlook
- Plan to continue driving Vafseo adoption across all dialysis providers, large and small.
- Expect to initiate a Phase 3 clinical trial (VALOR) for vadadustat in late-stage CKD patients not on dialysis in the second half of 2025.
- Believes it is financed to achieve profitability based on its current operating plan.
- Pursuing label expansion for Vafseo.
- Advancing other existing programs.
Challenges Ahead
- No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase risks.
- VAFSEO has not been studied and is not recommended in patients with active malignancies.
- The safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting.
- Actual results, performance or experience may differ materially from forward-looking statements due to various risks and uncertainties.
- Risks associated with the commercial availability of Vafseo, potential demand, market acceptance, and reimbursement.